| Survival in Pulmonary Hypertension Associated With the Scleroderma Spectrum of Diseases |
 |
 |
 |
| Thursday, 22 December 2011 20:02 |
|
Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, and Reda E. Girgis
Objective. Pulmonary hypertension (PH) is an important cause of mortality in systemic sclerosis (SSc), where it can be isolated (pulmonary arterial hypertension [PAH]) or associated with interstitial lung disease (ILD). This study was undertaken to characterize determinants of survival among SSc patients with either type of PH who received PAH-specific therapy. Methods. Consecutive SSc patients with PAH or ILD-associated PH confirmed by right heart catheterization were included in the study. Kaplan-Meier and Cox proportional hazards models were used to compare survival between SSc patients with PAH and those with ILD-associated PH and to identify predictors of survival. Results. Fifty-nine patients (39 with PAH and 20 with ILD-associated PH) were identified. The majority (15 of 20 with ILD-associated PH and 27 of 39 with PAH) received an endothelin receptor antagonist as initial therapy. Median followup time was 4.4 years (range 2.7–7.4 years). Survival was significantly worse in SSc patients with ILD-associated PH than in those with PAH (1-, 2-, and 3-year survival rates 82%, 46%, and 39% versus 87%, 79%, and 64%, respectively; P <0.01 by log rank test). In a multivariable analysis, ILD-associated PH was associated with a 5-fold increase in risk of death compared with PAH. Pulmonary vascular resistance index was also an independent predictor of mortality in the overall cohort (hazard ratio 1.05, P <0.01) and was a significant univariable risk factor in each group separately. Type of initial PAH therapy and the use of warfarin were not related to survival. Conclusion. Survival in SSc complicated by PH remains poor despite currently available treatment options. While therapy may be associated with improved survival in PAH compared with historical controls, the prognosis for patients with ILD-associated PH is particularly grim. Early diagnosis and treatment may improve outcomes since worsening hemodynamic factors were associated with reduced survival. |
More articles :
» Systemic Sclerosis Sine Scleroderma
HADI POORMOGHIM, MARY LUCAS, NOREEN FERTIG, and THOMAS A. MEDSGER, JR.ARTHRITIS & RHEUMATISM Vol. 43, No. 2, February 2000, pp 444–451 © 2000, American College of RheumatologyObjectiveTo describe the demographic, clinical, and laboratory...
» Scleroderma Treatment Options
Because no two cases of are alike, identifying your disease subtype, stage, and involved organs is very important in determining the best course of action for treatment. Current therapies use medications that focus on the four main features of the...
» Early Detection and Management of Pulmonary Arterial Hypertension
The long-term prognosis for patients with pulmonary arterial hypertension (PAH) remains poor, despite advances in treatment options that have been made in the past few decades. Recent evidence suggests that World Health Organization functional class...
» Vascular Complications of Systemic Sclerosis during Pregnancy
Eliza F. Chakravarty, MD MSSystemic sclerosis (SSc) is a chronic autoimmune disorder characterized by progressive fibrosis of the skin and visceral tissues as well as a non-inflammatory vasculopathy. Vascular disease in systemic sclerosis is a major...
» How To Know If Your Body Is Acidic?
It can be really crucial to remember that the are normally based on the quantity of acids we have in our body. These signs and symptoms are grouped according to it order of severity. Much less severe symptoms may well indicate that you simply are...
» Lupus and Rheumatoid Arthritis Affect Birth Rates
suggests that more than half of women with the autoimmune diseases (RA) and (SLE, or Lupus) have fewer children than they had desired.According to a study published Thursday in the journal Arthritis Care & Research (a journal of the American...